Introduction: Cerebral microbleeds (CMBs) are more frequent in patients with Alzheimer's disease (AD) than in the general population. However, their clinical significance remains poorly understood. We carried out a multimodal approach to evaluate the impact of CMBs at a clinical, neuropsychological, and survival level, as well as on core AD biomarkers in the cerebrospinal fluid (CSF) in AD patients.
Methods: We prospectively recruited 98 patients with mild-moderate AD. At baseline, they underwent brain MRI, and AD CSF biomarkers and APOE genotypes were analysed. An extensive neuropsychological battery was performed at baseline and after 1 year of follow-up. We analysed the stroke incidence and mortality with survival analyses.
Results: Forty-eight (48.5%) patients had at least one CMBs. Eight (8.2%) patients had strictly nonlobar CMBs, 39 (40.2%) had any lobar CMB locations. The incidence of stroke was higher in AD patients with lobar CMBs than in those without CMBs (p < 0.05). Mortality did not differ among groups (p > 0.05). At the cognitive level, CMBs patients deteriorated more rapidly at 12 months according to MMSE scores, with no differences observed at 24 months. We did not observe differences in the other tests, except for an increase in caregiver burden in the CMBs group. The presence of cerebral amyloidosis and APOE ε4 were associated with a greater presence of CMBs.
Conclusion: CMBs are associated with an increased risk of ischemic stroke in AD patients without differences in mortality. Patients with CMBs did not seem to have different consequences associated with cognitive decline except for an increase in caregiver overload.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520821 | PMC |
http://dx.doi.org/10.1186/s12877-022-03456-y | DOI Listing |
Cardiovasc Revasc Med
December 2024
Cardiovascular Center, Anjo Kosei Hospital, Anjo, Japan.
Background: The prognostic implications of cerebral microbleeds (CMBs) in patients who undergo transcatheter aortic valve replacement (TAVR) have not been fully elucidated. Therefore, we aimed to investigate the association between the presence of CMBs and adverse outcomes post-TAVR.
Methods: In this single-center retrospective study, we included 124 patients who underwent brain magnetic resonance imaging before TAVR.
Neurology
January 2025
Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX; and.
Objectives: Cerebral microbleeds (cMBs) are common imaging findings in conditions related to cerebral amyloid angiopathy (CAA). Blood-brain barrier (BBB) leakage is considered pivotal in their pathogenesis. This study investigates the potential role of cerebral microenhancement (cME) as an imaging biomarker on 3D T1 black-blood MRI (BB-MRI) for BBB rupture, predicting the formation of cMBs in inflammatory CAA variants.
View Article and Find Full Text PDFStroke
January 2025
Stroke Research Group, Department of Clinical Neurosciences, University of Cambridge, United Kingdom.
Background: How cerebral microbleeds (CMBs) are formed, and how they cause tissue damage is not fully understood, but it has been suggested they are associated with inflammation, and they could also be related to increased blood-brain barrier (BBB) leakage. We investigated the relationship of CMBs with inflammation and BBB leakage in cerebral small vessel disease, and in particular, whether these 2 processes were increased in the vicinity of CMBs.
Methods: In 54 patients with sporadic cerebral small vessel disease presenting with lacunar stroke, we simultaneously assessed microglial activation using the positron emission tomography ligand [11C]PK11195 and BBB leakage using dynamic contrast enhanced magnetic resonance imaging, on a positron emission tomography-magnetic resonance imaging system.
Intern Med J
December 2024
Medical and Cognitive Research Unit, Department of Geriatric Medicine, Austin Health, Melbourne, Victoria, Australia.
Background: Cerebral microbleeds (CMBs) are small brain haemorrhages, identified by magnetic resonance imaging (MRI). They indicate potential for cognitive decline and mortality in memory clinic attendees. The presence of more than four CMBs is exclusionary for some clinical trials of disease-modifying therapies for Alzheimer's disease (AD).
View Article and Find Full Text PDFFront Neurosci
December 2024
Department of Neurology, Affiliated Hospital of Hebei University, Baoding, China.
Background: Cerebral Microbleeds (CMBs) serve as critical indicators of cerebral small vessel disease and are strongly associated with severe neurological disorders, including cognitive impairments, stroke, and dementia. Despite the importance of diagnosing and preventing CMBs, there is a significant lack of effective predictive tools in clinical settings, hindering comprehensive assessment and timely intervention.
Objective: This study aims to develop a robust predictive model for CMBs by integrating a broad range of clinical and laboratory parameters, enhancing early diagnosis and risk stratification.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!